Amanat Acquisition Corp. agreed to combine with Corxel Pharmaceuticals, with closing expected in the first half of 2027. Management reported a $1,510,880 net loss from January 13, 2026 through September 30, 2026 and substantial doubt about its ability to continue as a going concern.
AMAN · Amanat Acquisition Corp. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
On October 25, 2026, Amanat Acquisition Corp agreed to a business combination with Corxel Pharmaceuticals, based on an implied Corxel equity value of $200,000,000. The combination is expected to close in the first half of 2027, following approvals by Amanat's shareholders and Corxel's sole stockholder. The PIPE Financing carries aggregate purchase commitments of $300 million, subject to reduction mechanisms.